All In Biotech

Drug Trial Radar · NCT04294810

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

620

Actual

Start

Mar 4, 2020

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • AtezolizumabDrug

    Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

  • TiragolumabDrug

    Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

  • Matching PlaceboDrug

    Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
  2. China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
  3. Global Cohort: Overall Survival (OS) in the PASTime frame: From randomization to death from any cause (up to approximately 54.7 months)
  4. China Cohort: OS in the PASTime frame: From randomization to death from any cause (up to approximately 49.1 months)
  5. Global Cohort: Number of Participants With Adverse Events (AEs)Time frame: Up to 65.1 months
  6. China Cohort: Number of Participants With AEsTime frame: Up to 49.3 months
  7. Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading ScaleTime frame: Up to 65.1 months
  8. China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading ScaleTime frame: Up to 49.3 months

Locations

132 sites in 23 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Center - Denver

    Denver, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • SCRI Florida Cancer Specialists North

    St. Petersburg, Florida

  • SCRI Florida Cancer Specialists PAN

    Tallahassee, Florida

  • US oncology research at Minnesota Oncology

    Saint Paul, Minnesota

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Virginia Cancer Specialists (Fairfax) - USOR

    Fairfax, Virginia

  • Onc & Hem Assoc SW Virginia

    Salem, Virginia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Austin Hospital Olivia Newton John Cancer Centre

    Heidelberg, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Ordensklinikum Linz Elisabethinen

    Linz, Austria

  • Klinik Penzing

    Vienna, Austria

  • Krankenhaus Nord - Klinik Floridsdorf

    Vienna, Austria

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Beijing Cancer Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Chongqing Cancer Hospital

    Chongqing, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Hainan General Hospital

    Haikou, China

  • Sir Run Run Shaw Hospital Zhejiang University

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Jinan Central Hospital

    Jinan, China

  • Meizhou People's Hospital

    Meizhou, China

  • The 1st Affiliated Hospital of Nanchang Unversity

    Nanchang, China

  • Nantong Tumor Hospital

    Nantong, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    Xi'an, China

  • Zhejiang Cancer Hospital

    Zhejiang, China

  • Krankenhaus Nordwest

    Frankfurt, Germany

  • LungenClinic Großhansdorf GmbH

    Großhansdorf, Germany

  • Krankenhaus Martha-Maria Halle-Doelau gGmbH

    Halle, Germany

  • Fachklinik für Lungenerkrankungen

    Immenhausen, Germany

  • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein

    Löwenstein, Germany

  • Gemeinschaftspraxis für Hämatologie und Onkologie

    Münster, Germany

Showing 40 of 132 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.